<DOC>
	<DOCNO>NCT02813252</DOCNO>
	<brief_summary>This study provide long-term follow-up patient receive treatment JCAR015 previous clinical trial . In study , patient follow 15 year last dose JCAR015 evaluation delay adverse event , presence persist JCAR015 vector sequence , survival .</brief_summary>
	<brief_title>Long-Term Follow-up Study Patients Previously Treated With JCAR015</brief_title>
	<detailed_description />
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Inclusion criterion : Patients receive least one dose JCAR015 previous treatment protocol . Patients provide informed consent longterm followup study prior study participation . Exclusion criterion : None . All patient previously receive JCAR015 treatment eligible longterm followup study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>long-term follow-up</keyword>
	<keyword>chimeric antigen receptor ( CAR ) T cell</keyword>
	<keyword>JCAR015</keyword>
</DOC>